)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Chemomab Therapeutics (CCMB) investor relations material
Chemomab Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 27th Annual Global Investment Conference summary5 Sep, 2025
Key presentations and announcements
Presented positive phase II results for nebokitug, a first-in-class monoclonal antibody targeting CCL24, in primary sclerosing cholangitis (PSC).
Nebokitug demonstrated significant anti-inflammatory and anti-fibrotic effects, meeting both primary (safety) and secondary (efficacy) endpoints in the phase II study.
The 20 mg/kg dose was selected for phase III, focusing on patients with moderate to advanced PSC.
High patient compliance observed, with 93% of eligible patients entering the open-label extension for up to 48 weeks.
FDA alignment achieved for a single pivotal phase III study, with plans to initiate soon and pursue full approval.
Industry analysis and competitive landscape
PSC is a rare liver disease with no approved treatments; current therapies only address symptoms, not disease progression.
Nebokitug is positioned as the only disease-modifying therapy in development for PSC, with potential to become the first approved drug for this indication.
Estimated commercial opportunity exceeds $1 billion annually due to high unmet need and premium pricing potential.
Strong interest from top-tier investors and potential strategic partners based on phase II results.
Forward-looking statements and development plans
Phase III study will evaluate clinical events beyond liver transplant and death, enabling a more feasible and timely trial.
Ongoing discussions with partners to support phase III initiation and commercialization.
Nebokitug's dual mechanism may have applications in other fibrotic diseases, with supporting data in systemic sclerosis and IPF.
Long-term safety and efficacy data support continued development and regulatory advancement.
Phase III clinical event endpoints
Nebucadnezar competitive differentiation
How did 48-week data compare to historical controls?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Chemomab Therapeutics earnings date
Q3 202514 Nov, 2025
Next Chemomab Therapeutics earnings date
Q3 202514 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Chemomab Therapeutics Ltd is an Israel-based clinical-stage biotechnology company focused on the development of therapies for fibrotic and inflammatory diseases. The company’s lead drug candidate is based on targeting CCL24, a chemokine involved in fibrosis and inflammation. Chemomab's pipeline includes treatments for conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis. The company conducts preclinical and clinical studies and collaborates with research institutions to advance its drug development efforts. Chemomab Therapeutics Ltd is headquartered in Tel Aviv, Israel, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage